Loss of fatty acid synthase inhibits the "hER2-PI3K/Akt axis" activity and malignant phenotype of Caco-2 cells

Lipids in Health and Disease

Volumn 12, Issue 1, 2013, Pages

  Li, Nan ^a   Lu, Heng ^a   Chen, Chunyan ^a   Bu, Xiaodong ^b   Huang, Peilin ^b  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^b MEDICAL SCHOOL OF SOUTHEAST UNIVERSITY   (China)

Author keywords

"HER2 PI3K Akt axis"; Caco 2 cells; FASN; Malignant phenotype

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FATTY ACID SYNTHASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

APOPTOSIS; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN CACO 2; COLONY FORMATION; COLORECTAL CANCER; CONTROLLED STUDY; DOWN REGULATION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PHENOTYPE; PLASMID; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING;

APOPTOSIS; CACO-2 CELLS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; ELAFIN; FATTY ACID SYNTHASE, TYPE I; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ONCOGENE PROTEIN V-AKT; RECEPTOR, ERBB-2; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

EID: 84878359486     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-12-83     Document Type: Article

References (31)

1. Fatty acid synthase activity in tumor cells. Little JL, Kridel SJ, Subcell Biochem 2008 49 169 194 10.1007/978-1-4020-8831-5-7 18751912
2. Fatty acid synthase is expressed mainly in adult hormone-sensitive cells or cells with high lipid metabolism and in proliferating fetal cells. Kusakabe T, Maeda M, Hoshi N, Sugino T, Watanabe K, Fukuda T, Suzuki T, J Histochem Cytochem 2000 48 5 613 622 10.1177/002215540004800505 10769045
3. Hypothalamic fatty acid metabolism: a housekeeping pathway that regulates food intake. López M, Lelliott CJ, Vidal-Puig A, Bioessays 2007 29 3 248 261 10.1002/bies.20539 17295284
4. Fatty acid synthase expression in endometrial carcinoma: correlation with cell proliferation and hormone receptors. Pizer ES, Lax SF, Kuhajda FP, Pasternack GR, Kurman RJ, Cancer 1998 83 3 528 537 10.1002/(SICI)1097- 0142(19980801)83:3<528::AID-CNCR22>3.0.CO;2-X 9690546
5. Key stages in mammary gland development. Secretory activation in the mammary gland: it's not just about milk protein synthesis! Anderson SM, Rudolph MC, McManaman JL, Neville MC, Breast Cancer Res 2007 9 1 204 10.1186/bcr1653 17338830
6. Immunohistochemical expression and prognostic significance of fatty acid synthase in pancreatic carcinoma. Alo PL, Amini M, Piro F, Pizzuti L, Sebastiani V, Botti C, Murari R, Zotti G, Di Tondo U, Anticancer Res 2007 27 4B 2523 2527 17695548
7. Differential expression of fatty acid synthase (FAS) and ErbB2 in nonmalignant and malignant oral keratinocytes. Silva SD, Cunha IW, Rangel AL, Jorge J, Zecchin KG, Agostini M, Kowalski LP, Coletta RD, Graner E, Virchows Arch 2008 453 1 57 67 10.1007/s00428-008-0626-5 18528705
8. Cohort study of fatty acid synthase expression and patient survival in colon cancer. Ogino S, Nosho K, Meyerhardt JA, Kirkner GJ, Chan AT, Kawasaki T, Giovannucci EL, Loda M, Fuchs CS, J Clin Oncol 2008 26 35 5713 5720 10.1200/JCO.2008.18.2675 18955444
9. Biochemistry, molecular biology, and pharmacology of fatty acid synthase, an emerging therapeutic target and diagnosis/prognosis marker. Liu H, Liu J-Y, Xi W, Zhang JT, Int J Biochem Mol Biol 2010 1 1 69 89 20706604
10. Transcriptome analysis of HER2 reveals a molecular connection to fatty acid synthesis. Kumar-Sinha C, Ignatoski KW, Lippman ME, Ethier SP, Chinnaiyan AM, Cancer Res 2003 63 1 132 139 12517789
11. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Zhang D, Tai LK, Wong LL, Chiu LL, Sethi SK, Koay ES, Mol Cell Proteomics 2005 4 11 1686 1696 10.1074/mcp.M400221-MCP200 16048908
12. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival. Menendez JA, Oza BP, Colomer R, Lupu R, Int J Oncol 2005 26 6 1507 1515 15870863
13. Diosgenin, a naturally occurring steroid, suppresses fatty acid synthase expression in HER2-overexpressing breast cancer cells through modulating Akt, mTOR and JNK phosphorylation. Chiang CT, Way TD, Tsai SJ, Lin JK, FEBS Lett 2007 581 30 5735 5742 10.1016/j.febslet.2007.11.021 18022396
14. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Furuta E, Pai SK, Zhan R, Bandyopadhyay S, Watabe M, Mo YY, Hirota S, Hosobe S, Tsukada T, Miura K, Kamada S, Saito K, Iiizumi M, Liu W, Ericsson J, Watabe K, Cancer Res 2008 68 4 1003 1011 10.1158/0008-5472.CAN-07-2489 18281474
15. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R, Lupu R, Proc Natl Acad Sci USA 2004 101 29 10715 10720 10.1073/pnas.0403390101 15235125
16. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Livak KJ, Schmittgen TD, Methods 2001 25 4 402 408 10.1006/meth.2001.1262 11846609
17. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Fiorentino M, Zadra G, Palescandolo E, Fedele G, Bailey D, Fiore C, Nguyen PL, Migita T, Zamponi R, Di Vizio D, Priolo C, Sharma C, Xie W, Hemler ME, Mucci L, Giovannucci E, Finn S, Loda M, Lab Invest 2008 88 12 1340 1348 10.1038/labinvest.2008.97 18838960
18. Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. Migita T, Ruiz S, Fornari A, Fiorentino M, Priolo C, Zadra G, Inazuka F, Grisanzio C, Palescandolo E, Shin E, Fiore C, Xie W, Kung AL, Febbo PG, Subramanian A, Mucci L, Ma J, Signoretti S, Stampfer M, Hahn WC, Finn S, Loda M, J Natl Cancer Inst 2009 101 7 519 532 10.1093/jnci/djp030 19318631
19. Targeting fatty acid synthase: potential for therapeutic intervention in her-2/neu-overexpressing breast cancer. Menendez JA, Lupu R, Colomer R, Drug News Perspect 2005 18 6 375 385 10.1358/dnp.2005.18.6.927929 16247515
20. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Vazquez-Martin A, Colomer R, Brunet J, Lupu R, Menendez JA, Cell Prolif 2008 41 1 59 85 10.1111/j.1365-2184. 2007.00498.x 18211286
21. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, Park BW, Kim KS, J Biol Chem 2007 282 36 26122 26131 10.1074/jbc.M702854200 17631500
22. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Grunt TW, Wagner R, Grusch M, Berger W, Singer CF, Marian B, Zielinski CC, Lupu R, Biochem Biophys Res Commun 2009 385 3 454 459 10.1016/j.bbrc.2009.05.085 19467222
23. Pharmacological inhibitors of Fatty Acid Synthase (FASN)-catalyzed endogenous fatty acid biogenesis: a new family of anti-cancer agents? Lupu R, Menendez JA, Curr Pharm Biotechnol 2006 7 6 483 493 10.2174/138920106779116928 17168665
24. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene. Menendez JA, Vellon L, Lupu R, Ann Oncol 2005 16 8 1253 1267 10.1093/annonc/mdi239 15870086
25. Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Vazquez-Martin A, Colomer R, Brunet J, Menendez JA, Int J Oncol 2007 31 4 769 776 17786307
26. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. Menendez JA, Decker JP, Lupu R, J Cell Biochem 2005 94 1 1 4 10.1002/jcb.20310 15523670
27. Fatty acid synthase-catalyzed de novo fatty acid biosynthesis: from anabolic-energy-storage pathway in normal tissues to jack-of-all-trades in cancer cells. Menendez JA, Lupu R, Arch Immunol Ther Exp (Warsz) 2004 52 6 414 426
28. Overexpression and hyperactivity of breast cancer-associated fatty acid synthase (oncogenic antigen-519) is insensitive to normal arachidonic fatty acid-induced suppression in lipogenic tissues but it is selectively inhibited by tumoricidal alpha-linolenic and gamma-linolenic fatty acids: a novel mechanism by which dietary fat can alter mammary tumorigenesis. Menendez JA, Ropero S, Mehmi I, Atlas E, Colomer R, Lupu R, Int J Oncol 2004 24 6 1369 1383 15138577
29. Molecular markers in ductal carcinoma in situ of the breast. Porter D, Lahti-Domenici J, Keshaviah A, Bae YK, Argani P, Marks J, Richardson A, Cooper A, Strausberg R, Riggins GJ, Schnitt S, Gabrielson E, Gelman R, Polyak K, Mol Cancer Res 2003 1 5 362 375 12651909
30. Inhibitor of fatty acid synthase induced apoptosis in human colonic cancer cells. Huang PL, Zhu SN, Lu SL, Dai ZS, Jin YL, World J Gastroenterol 2000 6 2 295 297 11819582
31. G inhibits protein synthesis, lipogenesis, and cell cycle progression through activation of AMPK in p53 positive and negative human hepatoma cells. Huang CH, Tsai SJ, Wang YJ, Pan MH, Kao JY, Way TD, Mol Nutr Food Res 2009 53 9 1156 1165 10.1002/mnfr.200800592 19662644